Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Talpaz

Showing results (311-320 of 350) with videos related to

Pageof 35
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1995
Collection of peripheral-blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive-dose chemotherapyH M Kantarjian, M Talpaz, J Hester, et al.
Blood|October 27, 1998
Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemiaZ Estrov, P F Thall, M Talpaz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1992
Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factorH M Kantarjian, M Talpaz, D Kontoyiannis, et al.
Journal of Cellular Physiology|March 1, 1996
Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181)Z Estrov, M Talpaz, T F Zipf, et al.
Blood|September 15, 1990
RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemiaC Hirsch-Ginsberg, A C LeMaistre, H Kantarjian, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|August 6, 2000
Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patientsC Kardinal, B Konkol, A Schulz, et al.
Leukemia|October 27, 1997
Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemiaH M Kantarjian, S M O'Brien, M Keating, et al.
Cancer|September 15, 1995
The breakpoint cluster region site in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Clinical, laboratory, and prognostic correlationsC F Verschraegen, H M Kantarjian, C Hirsch-Ginsberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1993
Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemiaS A Giralt, H M Kantarjian, M Talpaz, et al.
Blood|May 23, 1998
Loss of imprinting in disease progression in chronic myelogenous leukemiaG S Randhawa, H Cui, J A Barletta, et al.
Pageof 35

Showing results (311-320 of 350) with videos related to

Sort By:
Pageof 35
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1995
Collection of peripheral-blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive-dose chemotherapyH M Kantarjian, M Talpaz, J Hester, et al.
Blood|October 27, 1998
Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemiaZ Estrov, P F Thall, M Talpaz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1992
Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factorH M Kantarjian, M Talpaz, D Kontoyiannis, et al.
Journal of Cellular Physiology|March 1, 1996
Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181)Z Estrov, M Talpaz, T F Zipf, et al.
Blood|September 15, 1990
RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemiaC Hirsch-Ginsberg, A C LeMaistre, H Kantarjian, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|August 6, 2000
Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patientsC Kardinal, B Konkol, A Schulz, et al.
Leukemia|October 27, 1997
Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemiaH M Kantarjian, S M O'Brien, M Keating, et al.
Cancer|September 15, 1995
The breakpoint cluster region site in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Clinical, laboratory, and prognostic correlationsC F Verschraegen, H M Kantarjian, C Hirsch-Ginsberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1993
Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemiaS A Giralt, H M Kantarjian, M Talpaz, et al.
Blood|May 23, 1998
Loss of imprinting in disease progression in chronic myelogenous leukemiaG S Randhawa, H Cui, J A Barletta, et al.
Pageof 35